Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18898854 | Antibodies Targeting ActRIIA and ActRIIB | September 2024 | December 2024 | Abandon | 3 | 0 | 0 | No | No |
| 18890453 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18644619 | SYSTEM AND SENSOR ARRAY | April 2024 | February 2025 | Allow | 10 | 1 | 2 | No | No |
| 18417299 | ANTI-AMYLOID BETA PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOF | January 2024 | June 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18524613 | 3E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic colorectal cancer model | November 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18523859 | IMMUNOASSAY-BASED DETERMINATION OF IN-SOLUTION BINDING KINETICS | November 2023 | May 2025 | Allow | 18 | 1 | 0 | No | No |
| 18372933 | DEVICE AND METHOD FOR DETECTION OF ANALYTES | September 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18460221 | SYSTEM AND SENSOR ARRAY | September 2023 | March 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18460254 | METHODS AND DEVICES FOR ASSAYING A BIOLOGICAL SAMPLE | September 2023 | July 2024 | Allow | 10 | 3 | 1 | Yes | No |
| 18356985 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | July 2023 | June 2025 | Allow | 23 | 0 | 0 | No | No |
| 18357013 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | July 2023 | June 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18348398 | Early and Non Invasive Method for Assessing a Subject's Risk of Having Pancreatic Ductal Adenocarcinoma and Methods of Treatement of Such Disease | July 2023 | July 2024 | Allow | 12 | 0 | 0 | No | No |
| 18205581 | METHOD FOR FLUORESCENT IMMUNOASSAY (FIA) AND CHEMILUMINESCENT IMMUNOASSAY (CLIA) BASED ON ELECTROKINETIC ACCELERATION | June 2023 | October 2023 | Allow | 4 | 0 | 0 | No | No |
| 18329252 | IN SITU HEAT INDUCED ANTIGEN RECOVERY AND STAINING APPARATUS AND METHOD | June 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18295739 | SPR-BASED BRIDGING ASSAY FORMAT FOR DETERMINING THE BIOLOGICAL ACTIVITY OF MULTIVALENT, MULTISPECIFIC MOLECULES | April 2023 | February 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18182211 | CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR | March 2023 | January 2025 | Allow | 23 | 1 | 0 | No | No |
| 18044172 | Predicting Prognosis and Treatment Response of Breast Cancer Patients Using Expression and Cellular Localization of N-Myristoyltransferase | March 2023 | September 2023 | Allow | 6 | 0 | 0 | No | No |
| 18176283 | Tumor Antigens for Determining Cancer Therapy | February 2023 | April 2025 | Allow | 26 | 1 | 1 | No | No |
| 18053273 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | November 2022 | March 2025 | Allow | 28 | 1 | 0 | No | No |
| 17952919 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | September 2022 | July 2023 | Allow | 9 | 3 | 1 | No | No |
| 17906273 | METHOD FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A CANCER | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17930143 | ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF | September 2022 | August 2023 | Allow | 11 | 1 | 1 | No | No |
| 17855000 | MULTIFUNCTIONAL BEADS AND METHODS OF USE FOR CAPTURING CELLS | June 2022 | March 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17808420 | Early Detection Of Hepatocellular Carcinoma | June 2022 | May 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17839262 | AMYLOID BETA DETECTION BY MASS SPECTROMETRY | June 2022 | July 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17748522 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING, GERMLINE MISMATCH REPAIR DEFICIENCIES, LYNCH SYNDROME AND ASSESSING GERMLINE RISKS OF CANCER | May 2022 | March 2024 | Allow | 22 | 4 | 1 | Yes | No |
| 17743995 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | May 2022 | May 2023 | Allow | 12 | 1 | 2 | Yes | No |
| 17743961 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | May 2022 | May 2023 | Allow | 12 | 1 | 2 | Yes | No |
| 17739274 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | May 2022 | October 2022 | Allow | 6 | 2 | 0 | Yes | No |
| 17739278 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | May 2022 | February 2023 | Allow | 9 | 2 | 0 | No | No |
| 17720067 | METHODS OF MEASURING SIGNALING PATHWAY ACTIVITY FOR SELECTION OF THERAPEUTIC AGENTS | April 2022 | February 2025 | Allow | 34 | 2 | 0 | No | No |
| 17703354 | Hemostasis Measurement Device Quality Control Formulations | March 2022 | October 2023 | Allow | 18 | 0 | 0 | No | No |
| 17674400 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING, GERMLINE MISMATCH REPAIR DEFICIENCIES, LYNCH SYNDROME AND ASSESSING GERMLINE RISKS OF CANCER | February 2022 | March 2025 | Allow | 37 | 3 | 1 | Yes | No |
| 17651235 | METHODS OF CLASSIFYING RESPONSE TO IMMUNOTHERAPY FOR CANCER | February 2022 | March 2024 | Allow | 25 | 2 | 2 | No | No |
| 17665514 | PIPETTABLE REPLACEMENT FLUID FOR MIMICKING PIPETTABILITY OF TARGET FLUID AND RELATED METHOD | February 2022 | October 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17579437 | SINGLE CELL GENOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN METASTATIC DISEASE TO CHARACTERIZE DISEASE HETEROGENEITY | January 2022 | September 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17563279 | AUTOANTIBODY BIOMARKERS FOR THE EARLY DETECTION OF OVARIAN CANCER | December 2021 | September 2024 | Allow | 32 | 2 | 0 | No | No |
| 17645451 | METHOD FOR SCREENING PERSONALIZED INTESTINAL ENVIRONMENT-IMPROVING MATERIAL AND COMPOSITION THEREFOR | December 2021 | February 2025 | Allow | 38 | 2 | 0 | No | No |
| 17557988 | THERAPEUTIC ANTICANCER NEOEPITOPE VACCINE | December 2021 | March 2024 | Allow | 27 | 0 | 0 | No | No |
| 17558421 | METHODS AND KITS | December 2021 | January 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17511750 | METHOD FOR TRAINING AND TESTING SHORTCUT DEEP LEARNING MODEL CAPABLE OF DIAGNOSING MULTI-CANCER USING BIOMARKER GROUP-RELATED VALUE INFORMATION AND LEARNING DEVICE AND TESTING DEVICE USING THE SAME | October 2021 | September 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17507320 | RAPID MEASUREMENT OF TOTAL VITAMIN D IN BLOOD | October 2021 | September 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17601054 | CONJUGATES HAVING AN ENZYMMATICALLY RELEASABLE DETECTION MOIETY AND A BARCODE MOIETY | October 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17598185 | MULTIGENE ASSAY TO ASSESS RISK OF RECURRENCE OF CANCER | September 2021 | March 2025 | Allow | 42 | 0 | 1 | No | No |
| 17482700 | METHODS FOR REDUCING INTERFERENCES | September 2021 | April 2025 | Allow | 43 | 2 | 0 | No | No |
| 17436744 | ANTI-BIOTIN ANTIBODY AND APPLICATION THEREOF | September 2021 | January 2023 | Allow | 17 | 2 | 0 | Yes | No |
| 17465101 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | September 2021 | January 2023 | Allow | 16 | 3 | 0 | No | No |
| 17465096 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | September 2021 | October 2022 | Allow | 13 | 3 | 0 | Yes | No |
| 17409168 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | August 2021 | February 2024 | Allow | 30 | 1 | 0 | No | No |
| 17310274 | LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING | July 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17385508 | METHODS OF INHIBITING LYSINE-SPECIFIC DEMETHYLASE 1 (LSD-1) | July 2021 | September 2023 | Allow | 26 | 1 | 1 | No | No |
| 17378829 | METHODS AND KITS FOR PREDICTING PROGNOSIS OF CANCER USING SOLUBLE MORTALIN IN BLOOD | July 2021 | November 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17422444 | DEVICES AND METHODS FOR TISSUE AND CELL STAINING (II) | July 2021 | August 2024 | Allow | 37 | 3 | 1 | No | No |
| 17354656 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | June 2021 | September 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17354653 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | June 2021 | September 2022 | Allow | 15 | 3 | 0 | Yes | No |
| 17297599 | APTAMERS AGAINST IMATINIB | May 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17296752 | ANTI-4-1BB ANTIBODY AND USE THEREOF | May 2021 | September 2024 | Allow | 39 | 1 | 0 | No | No |
| 17309221 | MONOCLONAL ANTIBODIES AGAINST LORICRIN | May 2021 | June 2025 | Allow | 50 | 1 | 1 | No | No |
| 17283902 | B7H3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF | April 2021 | June 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17281663 | ANTIBODIES TARGETING EPN1 | March 2021 | April 2025 | Allow | 49 | 1 | 1 | No | No |
| 17215923 | SYSTEM AND SENSOR ARRAY | March 2021 | May 2022 | Allow | 14 | 2 | 1 | Yes | No |
| 17188006 | MITOCHONDRIAL PROTEASE OMA1 AS A MARKER FOR BREAST CANCER | March 2021 | January 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17272000 | Activation of Antigen Presenting Cells and Methods for Using the Same | February 2021 | June 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17169033 | KIT AND METHOD FOR DETERMINING PROSTATE CANCER MALIGNANCY | February 2021 | May 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17161783 | ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINS | January 2021 | February 2024 | Allow | 37 | 1 | 1 | No | No |
| 17131339 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | December 2020 | March 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17131326 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | December 2020 | March 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17131328 | CHECKPOINT BLOCKADE AND MICROSATELLITE INSTABILITY | December 2020 | March 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17058143 | NOVEL MONOCLONAL ANTIBODY HAVING ANTI-INFLAMMATORY ACTION | November 2020 | December 2024 | Abandon | 49 | 1 | 1 | No | No |
| 17101693 | MEANS AND METHODS FOR DETERMINING RISK OF TYPE-1 DIABETES BY SERUM PROTEIN BIOMARKERS | November 2020 | February 2024 | Allow | 38 | 1 | 0 | No | No |
| 17090566 | METHODS OF PROMOTING CNS NEURONAL REPAIR BY INHIBITING LRP-1 | November 2020 | March 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17078417 | Methods of Detecting and Preventing Atopic Allergic Diseases | October 2020 | March 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17069349 | NOVEL ANTI-THYMIDINE KINASE ANTIBODIES | October 2020 | April 2024 | Allow | 42 | 0 | 1 | No | No |
| 17062279 | DIRECT AFFINITY MEASUREMENT OF HUMAN IGG1 BINDING MULTIMERIC ANTIGENS | October 2020 | December 2024 | Allow | 51 | 2 | 1 | No | No |
| 17062302 | METHOD FOR DETERMINING THE IN VIVO INTERACTION MODE | October 2020 | December 2023 | Allow | 38 | 1 | 0 | No | No |
| 16948556 | TEMPORAL PEDIATRIC SEPSIS BIOMARKER RISK MODEL | September 2020 | June 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17021894 | TARGETING METASTASIS STEM CELLS THROUGH A FATTY ACID RECEPTOR (CD36) | September 2020 | December 2024 | Allow | 51 | 3 | 0 | No | No |
| 17011397 | IN SITU HEAT INDUCED ANTIGEN RECOVERY AND STAINING APPARATUS AND METHOD | September 2020 | January 2023 | Allow | 29 | 1 | 0 | No | No |
| 17003139 | BIOMARKERS FOR PANCREATIC CANCER | August 2020 | January 2024 | Allow | 40 | 0 | 1 | No | No |
| 16998990 | SPR-BASED BRIDGING ASSAY FORMAT FOR DETERMINING THE BIOLOGICAL ACTIVITY OF MULTIVALENT, MULTISPECIFIC MOLECULES | August 2020 | April 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16987118 | ANTIBODIES THAT BIND TO AXL PROTEINS | August 2020 | April 2023 | Allow | 32 | 1 | 0 | No | No |
| 16987100 | ANTIBODIES THAT BIND TO AXL PROTEINS | August 2020 | April 2023 | Allow | 32 | 1 | 0 | No | No |
| 16937284 | METHODS AND COMPOSITIONS FOR PHOTOTRANSFER | July 2020 | January 2024 | Abandon | 42 | 2 | 1 | No | No |
| 16932626 | METHOD FOR SCREENING PERSONALIZED INTESTINAL ENVIRONMENT-IMPROVING MATERIAL AND COMPOSITION THEREFOR | July 2020 | September 2021 | Allow | 14 | 1 | 1 | No | No |
| 16960844 | DIAGNOSTIC TEST | July 2020 | September 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16959595 | METHOD FOR DETERMINING DYSBIOSIS IN THE INTESTINAL MICROBIOME | July 2020 | August 2024 | Allow | 49 | 1 | 1 | No | No |
| 16912087 | METHOD FOR PREDICTING CANCER SENSITIVITY | June 2020 | January 2023 | Allow | 31 | 1 | 0 | No | No |
| 16887142 | METHODS FOR IMPROVEMENT OF SEMEN QUALITY | May 2020 | July 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16860333 | KIT FOR IN VITRO OR EX VIVO MEASUREMENT OF THE EXPRESSION OF sCD127 IN A BIOLOGICAL SAMPLE | April 2020 | September 2023 | Abandon | 41 | 2 | 0 | Yes | No |
| 16851841 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | April 2020 | June 2022 | Allow | 26 | 0 | 0 | No | No |
| 16647434 | METHODS OF CLASSIFYING RESPONSE TO IMMUNOTHERAPY FOR CANCER | March 2020 | April 2023 | Allow | 37 | 4 | 1 | Yes | No |
| 16644545 | METHOD FOR DETECTING PROSTATE CANCER | March 2020 | December 2023 | Abandon | 46 | 0 | 1 | No | No |
| 16750807 | DEVICE AND METHOD FOR DETECTION OF ANALYTES | January 2020 | June 2023 | Allow | 40 | 3 | 0 | No | No |
| 16733829 | COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION | January 2020 | August 2020 | Allow | 8 | 1 | 1 | Yes | No |
| 16625142 | METHODS FOR DETECTING OVARIAN CANCER | December 2019 | January 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16622499 | COMPOSITIONS AND METHODS FOR PREDICTING POST-SURGICAL CARDIOVASCULAR EVENTS | December 2019 | August 2024 | Allow | 56 | 2 | 1 | No | No |
| 16617423 | METHODS OF DETERMINING THERAPIES BASED ON SINGLE CELL CHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCS) IN METASTATIC DISEASE | November 2019 | June 2024 | Abandon | 55 | 1 | 1 | No | No |
| 16616523 | MARKERS OF TOTIPOTENCY AND METHODS OF USE | November 2019 | June 2025 | Allow | 60 | 4 | 1 | No | No |
| 16616316 | Novel stool-based protein biomarkers for colorectal cancer screening | November 2019 | August 2024 | Abandon | 57 | 2 | 2 | No | No |
| 16691788 | AFFINITY-BASED DETECTION OF LIGAND-ENCODED SYNTHETIC BIOMARKERS | November 2019 | January 2024 | Allow | 49 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COOK, LISA V.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COOK, LISA V works in Art Unit 1642 and has examined 366 patent applications in our dataset. With an allowance rate of 72.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 39 months.
Examiner COOK, LISA V's allowance rate of 72.7% places them in the 28% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by COOK, LISA V receive 1.96 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by COOK, LISA V is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +15.3% benefit to allowance rate for applications examined by COOK, LISA V. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 26.9% of applications are subsequently allowed. This success rate is in the 36% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 35.1% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 76.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.4% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 4.4% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.